Does anyone have any info about how things are going with Warner Lambert & Smithkline? I know they a behind on their contract and are currently in the penalty phase, but has there been any progress on an agreement to delay the penalties?p.s. - ha anyone else noticed that this stock very closey follows Celera? Graph the two of them over the past few months and see what I mean. Just curious.
Movements of ABSC have indeed been strongly correlated with those of CRA, as have most of the so-called "genomics" companies -- AFFX, INCY, HGSI. The tendency of stocks in the same sector to move together isn't surprising. And Celera's victories on the sequencing event should in fact vitalize the entire industry, improving the potential content of AFFX's gene chips (which can then more-completely represent the genome) and increasing the need for ABSC's high-throughput screening technology (which promises to turn the most interesting of those newly-discovered genes into useful drugs).What is surprising is investors' failure to distinguish among genomics stocks when news events clearly don't affect them the same way.Case in point: the issue of gene patents. This issue doesn't unify the biotech sector, it divides it. Outside of the companies that are actually doing the sequencing (e.g. Celera and Incyte), most of the industry would love to see sequence-based gene patents be limited in scope.... Suppose the judicial system does in fact curtail the scope of gene patents, particularly those based primarily sequence information alone (rather than on insights about gene function). Such a desicion would compromise the sequence-based patents which Celera and Incyte are filing on the genes they discover. But a company like ABSC isn't in the business of patenting gene sequences -- in fact, with their GenomeScreen technology, they're in the business of discovering what genes actually do. So a challenge to sequence-based patents would likely heat up demand for Aurora's technology.... Anyway, the Clinton-Blair announcement caused a selloff in the whole genomics sector, even though many genomics companies probably would have considered it good news.An analogy may be in the way the Judge Jackson's decision in the Microsoft case caused a selloff in the computer industry, even though most of the computer industry (outside of Microsoft) would love to see Microsoft's reign of terror curtailed.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |